AstraZeneca lung cancer drug given green light in US

FDA approval of Tagrisso offers major boost for British company, seeking to release six new cancer medicines by 2020A new lung cancer pill from AstraZeneca has been approved by US regulators, in a major boost for the British drugmaker.AZD9291, which will be sold as Tagrisso, is for advanced non-small-cell lung cancer, the most common form of lung cancer. Tagrisso targets a genetic mutation, known as T790M, that helps tumours evade current lung cancer pills. The drug will be made available to patients in the US as soon as possible and its price will be “comparable to other oral cancer therapies,” a spokeswoman said. AstraZeneca will reveal the price early next week. Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Business Pharmaceuticals industry Cancer Health Society Medical research Source Type: news

Related Links:

AbstractDabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor), for unresectable or metastaticBRAF-mutated melanoma, advanced non-small cell lung cancer and anaplastic thyroid cancer harbouring theBRAFV600E mutation. The recommended dose of dabrafenib is 150  mg twice daily (bid) under fasted conditions. After single oral administration of the recommended dose, the absolute oral bioavailability (F) of dabrafenib is 95%. Dabrafenib shows a time-dependent increase in appa...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Abemaciclib demonstrated an acceptable safety profile when dosed on a continuous twice-daily schedule in combination with pemetrexed, gemcitabine, or ramucirumab. Abemaciclib exposures remained consistent with those observed in single-agent studies. PMID: 30082474 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractPurpose of ReviewSince the identification of multiple mutations associated with advanced non-small cell lung cancer (NSCLC), many targeted therapies have been developed for the treatment of this subgroup of lung cancers. These targeted therapies have changed the landscape of lung cancer treatment when compared to standard chemotherapy, with improved survival and quality of life. In this review article, we will review the major mutations associated with advanced NSCLC, namely EGFR, ALK, and ROS1. We will discuss their discovery, their clinical significance, and the diagnostic tests used for their detection. We will ...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
Authors: Oh SH, Byun HJ, Oh SJ, Jun JY, Park JH, Lee JH, Lee DY, Lee JH, Yang JM Abstract Drug induced lichen planus like eruption is an uncommon cutaneous adverse effect of several drugs. This appears symmetric eruption of erythematous or violaceous plaques resembling lichen planus on the trunk and extremities. A 50-year-old male presented with scaly, violaceous plaques and dusky brown macules on whole body. For four months, the patient was treated with olmutinib, an oral, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor. In May 2016, olmutinib received its first global approval in South...
Source: Annals of Dermatology - Category: Dermatology Tags: Ann Dermatol Source Type: research
Rationale: Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), a distinct molecular entity, is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib or ceritinib. Interstitial lung disease is a rare (1.2%) pulmonary toxicity that can result from ALK TKIs, however, organizing pneumonia has not been reported to date. Patient concerns: A 45-year-old Korean female with ALK-rearranged metastatic lung adenocarcinoma underwent ceritinib treatment and exhibited a partial response, until she developed organizing pneumonia resembling disease progression. Diagnoses: M...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
AbstractAlectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advancedALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with advancedALK-positive NSCLC previously treated with crizotinib. In the USA, alectinib is indicated for the treatment of adults withALK-positive metastatic NSCLC. The recommended dosage for alectinib in the EU and USA is 600  mg twice daily. Well-designed phase III studies in patients withALK-positive NSCLC showed th...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
In conclusion, apatinib shows some efficacy in heavily treated NSCLC and generally tolerable toxicity in non-squamous NSCLC. More solid evidence will be accessible in near future.
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
ConclusionsA large proportion of the study patients started minocycline before grade 2 rash development and the severity of afatinib-related rash was lower than that previously reported. Oral TCs may be beneficial, especially if started early.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
In conclusion, apatinib shows some efficacy in heavily treated NSCLC and generally tolerable toxicity in non-squamous NSCLC. More solid evidence will be accessible in near future.
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
AbstractOsimertinib (Tagrisso®) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mutation that often underlies acquired resistance to earlier generation EGFR TKIs. Relative to standard of care first-generation EGFR TKIs (erlotinib or gefitinib) as first-line treatment ofEGFR activating mutation-positive advanced NSCLC, osimertinib significantly prolongs median progression-free survival (PFS), with sep...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research | Science